Consequently, this proof-of-concept study aimed to launch and verify a radiomic signature to predict PFS in stage IV ALK-positive NSCLC patients treated with TKI crizotinib, and further investigate the association of this radiomic signature with PFS in EGFR-mutant NSCLC patients with EGFR-TKI therapy. The gene discussed is ALK; the disease is non-small cell lung carcinoma.